To: Robert O who wrote (13284) | 9/9/2020 3:37:07 PM | From: E_K_S | | | No, it's fine. I have it bookmarked so I do pay attention to your Buys/Sells. Might be good to also mention if you keep a portion for a longer term hold.
I do some swing trades where I Buy a double position and then let 50% go and keep 50% for the portfolio.
The key is you identify a bottom and/or trading opportunity which may/could also be a good entry point for a long term buy/hold.
Good Investing
EKS |
| Full Disclosure Trading | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
To: Robert O who wrote (13287) | 9/15/2020 4:28:22 PM | From: Robert O | | | IMMU ST-MT BOT 1000 @ 84.69 at close
hope to build a larger position will see if further action merits.
for color- had a lower limit order in for last 15 mins, method is if I sense going to miss a fill but not by much will put in a slightly higher limit order with 1-2 minute left (when MM will often get a little 'bouncy' to try and scoop limits) but only if shares have sold off enough already that it's still a fill I want. never willing to chase it, though can have regrets of course. Also yest end of day was perfect opportunity here but for all kinds of reasons I wasn't watching. used to curse the heavens then watch what could have still been profits escape me. more mature now, better to take what it gives if it's still a net desirable play. |
| Full Disclosure Trading | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
To: Robert O who wrote (13289) | 9/23/2020 3:40:48 PM | From: Robert O | | | IMMU ST-MT BOT 1500 @ 85.21
n.b. (New York, September 23, 2020 -- Moody's Investors Service ("Moody's") assigned an A3 rating to the new senior unsecured note offering of Gilead Sciences, Inc. ("Gilead"). There are no changes to Gilead's existing A3 senior unsecured ratings, and the outlook remains unchanged at negative. Proceeds of the offering together with cash on hand and proceeds from a new senior unsecured term loan are intended to be used to fund Gilead's pending acquisition of Immunomedics, Inc. and to pay 2021 debt maturities.) |
| Full Disclosure Trading | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
To: Robert O who wrote (13278) | 10/14/2020 11:16:30 AM | From: Robert O | | | AIMT SOLD 10,000 @ 34.50
+$2,600
Tender buyout completed. Accumulated addl shares even as it approached tender date as alternative to sitting in cash bringing my cost basis up to 34.24 Holding times from a month to 45 days for initial buy. |
|
| Full Disclosure Trading | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| |